NIFTY  9,360.55  -0.27%
  SENSEX  30,301.60  -0.21%
 CURRENCY  Rs  64.89/$ 72.59/€, 84.18/£
  GOLD  28,710.00  -0.35%
  SILVER  39,830.00  -0.32%
  DAX  12,642.90  -0.13%
  FTSE  7,514.90  0.40%
  CAC  5,341.34  -0.11%
  HANG SENG  25,428.50  0.10%
  NIKKEI  19,743.00  0.66%
  Shanghai Composite  3,064.08  0.03%
  DOW JONES  20,937.90  0.21%
  NASDAQ  6,138.71  0.08%
  S&P 500  2,398.42  0.18%
SOURCES TO COGENCIES : Cabinet Approves Proposal For Abolition Of Foreign Investment Promotion Board SOURCES TO COGENCIES : Cabinet Approves Proposal On 2017-18 Sugarcane Prices SOURCES TO COGENCIES : Need For Cabinet Nod For FDI Over Rs 5000 Cr To Remain TATA INVEST Q4 EARNINGS : PAT Rs 16.1 Cr Vs Rs 22.3 Cr YoY TATA INVEST Q4 EARNINGS : Revenue Rs 35.8 Cr Vs Rs 32.3 Cr YoY TATA INVEST Q4 EARNINGS : To Pay Dividend Of Rs 18/Share PRASUN GAJRI HDFC LIFE : I.T. Stocks May Perform Better On A Short-Term Basis FROM REUTERS : KOC & Tata Group Sign Joint Venture To Tap Into White Goods Consumer Market

Excluding R&D, Q1 Margins At 28%: Biocon

Video:

Play this video

July 26: Bloomberg TV India asks Biocon Chairman and MD Kiran Mazumdar Shaw about the company’s outlook. She says the company aims to maintain healthy EBITDA margins, which will allow Biocon to continue investing in its R&D programmes.